## Original Article Overexpression of long non-coding RNA CCAT2 predicts a poor prognosis in patients with oral squamous cell carcinoma

Niangou Zhou<sup>1</sup>, Wei Liao<sup>1</sup>, Zikun Huang<sup>2</sup>, Zuowen Hu<sup>1</sup>, Weizhong Huang<sup>1</sup>, Qiutao Wang<sup>1</sup>

<sup>1</sup>Department of Stomatology, 421 Hospital of PLA, Guangzhou, Guangdong, China; <sup>2</sup>Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Received October 7, 2015; Accepted November 22, 2015; Epub January 1, 2016; Published January 15, 2016

Abstract: Introduction: Long non-coding RNA CCAT2 (IncRNA CCAT2) have been demonstrated to be a critical role in cancer progression and prognosis. However, its effects in oral squamous cell carcinoma (OSCC) have not been explored. The aim of this study was to investigate the expression and clinical significance of IncRNA CCAT2 in human OSCC. Methods: Expression levels of IncRNA CCAT2 in 102 OSCC tissues and cell lines were examined by quantitative real-time PCR (qRT-PCR). The correlation of IncRNA CCAT2 with clinicopathological features and prognosis was analyzed. Moreover, in vitro assays were performed to explore its role in OSCC progression. Results: The expression level of IncRNA CCAT2 was significantly higher in tumor tissues and oral cancer cell lines than in adjacent non-tumor tissues and normal human oral keratinocyte cells. High expression of IncRNA CCAT2 was found to significantly correlate with tumor grade, TNM stage and distant metastasis. Moreover, OSCC patients with IncRNA CCAT2 higher expression have shown significantly poorer overall survival than those with lower IncRNA CCAT2 expression. Univariate and multivariate analyses suggested that high expression of IncRNA CCAT2 was an independent poor prognostic indicator for OSCC patients. In vitro assays, our data indicated that downregulation of CCAT2 decrease cell proliferation, migration, and invasion ability. Conclusions: High IncRNA CCAT2 expression is associated with poor prognosis in OSCC and may serve as a novel prognostic marker in OSCC.

Keywords: Oral squamous cell carcinoma, LncRNA CCAT2, overall survival, prognosis

#### Introduction

Oral squamous cell carcinoma (OSCC) is one of the most lethal malignancies worldwide and is also the most common oral cancer [1]. OSCC is accompanied by frequent metastasis, high recurrence and poor prognosis. It has been estimated that worldwide, more than 100,000 deaths result from OSCC annually [2]. Despite much progress in early detection and treatment, the 5-year survival rate worldwide for OSCC remains below 60% [2]. Therefore, it is necessary for us to discover the underlying molecular mechanisms and screen useful biomarkers and novel therapeutic targets of OSCC.

Long non-coding RNAs (IncRNAs) are more than 200 nucleotides in length with limited or no protein-coding capacity and serve as the primary regulatory non-coding RNA [3]. LncRNAs have been implicated in a large number of cellular processes, such as cell proliferation, cell cycle progression, cell growth and cell apoptosis [4, 5]. Emerging evidences indicate that IncRNAs may play complex and extensive roles in promoting the development and progression of cancer. For example, Chen et al. found that IncRNA HOTAIR was up-regulated in esophageal squamous cell carcinoma tissues and associated with tumor size, TNM stage and poor prognosis of esophageal squamous cell carcinoma [6]. Further experiments suggested that HOTAIR exerts its oncogenic functions via binding the PRC2 (polycomb repressive complex 2), which methylates histone H3 on K27 to promote gene repression [7]. Hua et al. indicated that IncRNA ANRIL up-regulated in human hepatocellular carcinoma tissues and correlated with a higher histologic grade and TNM stage [8]. They suggested that ANRIL expression served as an

Parameters	Group	Total	IncRNA CCAT2		P value
			Low	High	-
Age (years)	< 60	48	20	28	0.638
	≥ 60	54	25	29	
Gender	Male	62	28	34	0.792
	Female	40	17	23	
Tumor location	Tongue	40	16	24	0.385
	Floor of mouth	4	3	1	
	Buccal mucosa	25	12	13	
	Hard palate	7	4	3	
	Upper or lower gingival	26	10	16	
Tumor size	T1-T2	45	18	27	0.457
	T3-T4	57	27	30	
Tumor grade	G1	40	25	15	0.003
	G2/G3	62	20	42	
Distant metastasis	Yes	43	5	38	0.000
	No	59	40	19	
TNM stage	1-11	38	23	15	0.010
	III-IV	64	22	42	

 Table 1. Clinicopathological features and the expression of

 IncRNA CCAT2 in OSCC patients

independent predictor for overall survival of hepatocellular carcinoma patients. Sun et al. reported that GAS5 down-regulation was involved in gastric cancer tumorigenesis and progression, ectopic expression of GAS5 could decrease gastric cancer cell proliferation and induce apoptosis in via regulating E2F1 and P21 [9]. Dysregulation of certain IncRNAs are related to prognosis, metastasis, and recurrence in different cancer types. However, the role of IncRNAs in OSCC development has only recently been investigated and remains largely unknown.

LncRNA CCAT2 (colon cancer-associated transcript 2) was firstly identified and found highly expressed in microsatellite-stable colorectal cancer [10]. CCAT2 is located within the 8q24 gene desert region and includes a cancer-related single nucleotide polymorphism rs69832-76. Recently, various studies have shown that IncRNA CCAT2 plays a crucial role in regulation of cancer cell biological functions. In addition, overexpression of IncRNA CCAT2 has been found in several types of cancers such as esophageal squamous cell carcinoma [11], gastric cancer [12], breast cancer [13], and lung cancer [14]. However, the IncRNA CCAT2 expression in OSCC and underlying mechanism is still unknown.

CCAT2 levels in tumor tissues and the clinicopathological features of OSCC. Finally, we conducted in vitro assays to demonstrate the biological functions of CCAT2 in OSCC development and progression. **Material and methods** *Patients and samples* The 102 OSCC patients were

In the present study, we investi-

gated the expression of IncRNA

CCAT2 in OSCC tissues and oral cancer cell lines. We then examined the relationships between

from the Department of Stomatology, 421 Hospital of PLA (Guangzhou, China), diagnosed with OSCC between January 2007 and June 2009. OSCC was confirmed in all cases by histological examination of tissue from biopsy specimens. Tumor

stage was classified according to the 7<sup>th</sup> edition of the classification of malignant tumors of the American Joint Committee on Cancer [15]. Tumor grade was classified following the WHO criteria [16]. All patients did not receive chemotherapy or radiotherapy prior to surgery. Clinicopathological characteristics in our study are presented in **Table 1**. After surgical resection, tumor specimens and adjacent non-tumor tissues were collected and stored in liquid nitrogen until use. This study was approved by the Research Ethics Committee of the 421 Hospital of PLA. Written informed consent was obtained from all patients.

## Cell culture and transfection

Three oral cancer cell lines (Tca8113, SCC25 and CAL27), and a human immortalized oral keratinocyte cell line (HOK16E6E7) were purchased from the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). Oral cancer cells were cultured in RPMI 1640 or Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin, and 100 mg/ml streptomycin. HOK16E6E7 were cultured in keratinocyte growth medium containing 0.15 mM calcium and supplemented with epidermal growth factor (Gibco). All cells were cultured at  $37^{\circ}$ C in a humidified atmosphere with 5% CO<sub>2</sub>.

Tca8113 cells were transfected with either 50 nM siRNAs targeting CCAT2 (si-CCAT2) or scrambled negative controls (si-NC) (Gene-Pharma, China) using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the instructions provided by the manufacturer. The target sequence for CCAT2 siRNAs was 5'-UUAACCUCUUCCUAUCUCATT-3' [11]. After 48 hours, cells transfected with siRNA were harvested for qRT-PCR to determine the transfection efficiency.

# RNA extraction and quantitative real-time PCR (qRT-PCR)

Total RNAs were extracted from tumorous and adjacent normal tissues or cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. For gRT-PCR, RNA was reverse transcribed to cDNA by using a Reverse Transcription Kit (Takara, Dalian, China). Real-time PCR analyses were performed with Power SYBR Green (Takara, Dalian China). Results were normalized to the expression of GAPDH. The PCR primers for CCAT2 or GAPDH were as follows: CCAT2 sense, 5'-CCCTGGTCA-AATTGCTTAACCT-3' and reverse, 5'-TTATTCGT-CCCTCTGTTTTATGGAT-3'; GAPDH sense, 5'-GC-ACCGTCAAG GCTGAGAAC-3' and reverse, 5'-TG-GTGAAGACGCCAGTGGA-3'. qRT-PCR and data collection were performed on ABI 7500. The fold change between tumor tissues and noncancerous samples for IncRNA CCAT2 was calculated with the 2-DACT method. The expression levels of IncRNA CCAT2 in HOK16E6E7, Tca8113, SCC25, and CAL27 were detected using the same method. qRT-PCR was repeated in triplicate for each sample.

#### Cell proliferation assay

The proliferation of Tca8113 cells was evaluated using the MTT (Sigma) assay according to the manufacturer's instructions. Tca8113 cells that had been transfected with either si-CCAT2 or si-NC for 48 hours were reseeded into 96well plates. Cell density was adjusted to  $5 \times 10^3$ / well, and the final volume was  $150 \mu$ /well. MTT solution (20 µl) was added to the plates 24, 48, 72, and 96 hours later. The cells were cultured for 4 hours at 37°C. Then, the medium was discarded and 150 µl DMSO was added and oscillated for 15 min. The absorbance was measured at 490 nm using an enzyme-labeled analyzer. Three independent experiments were performed.

### Cell migration assays

Migration ability was measured using a wound healing assay. Tca8113 cells transfected with either si-CCAT2 or si-NC were seeded into 6-well plates, incubated in their respective complete culture medium and grown to confluence over-night. The monolayer was scratched and then incubated in fresh medium for 24 hours. The width of the wound was measured after 24 hours. Three different locations were visualized and photographed with a phasecontrast inverted microscope (Leica, Solms, Germany).

### Transwell invasion assay

Cell invasion assays was performed using 24-well Transwells (8-µm pore size, Corning Life Sciences) coated with 1 mg/ml Matrigel (BD Sciences), Tca8113 cells transfected with either si-CCAT2 or si-NC were collected and resuspended in serum-free medium at a concentration of 1×10<sup>5</sup> cells/ml, respectively. The cells were seeded in the upper chamber of the wells in 200 µl FBS-free medium, and the lower chambers were filled with 500 µl 20% FBS medium. Following incubation for 48 hours at  $37^{\circ}C$ , 5%  $CO_{2}$ , the cells on the filter surface were fixed with methanol, stained with 0.1% crystal violet, and photographed with a phasecontrast inverted microscope (Leica). The cells from at least five random microscopic fields (×100) were counted.

## Statistical analysis

All statistical analyses were performed using SPSS 17.0 software (IBM, SPSS, Chicago, IL, USA). Comparison of continuous data was analyzed using an independent *t*-test between the two groups, whereas categorical data was analyzed by the chi-square test. Overall survival curves were plotted according to the Kaplan-Meier method, with the log-rank test applied for comparison. A Cox proportional hazards regression analysis was used for univariate and multivariate analyses of prognostic values. The data are shown as the mean ± SD from at least three independent experiments. Two-sided *P* values



**Figure 1.** LncRNA CCAT2 expression levels in OSCC tissues and oral cancer cells. The levels of CCAT2 were assessed by qRT-PCR, using GAPDH as a normalisation control. A. The CCAT2 expression levels in OSCC samples were significantly higher than those in adjacent non-tumor tissues. B. Higher expression levels of CCAT2 were detected in 3 oral cancer cell lines than in immortalized oral keratinocyte cell line HOK16E6E7. Results were expressed as mean  $\pm$  SD for three replicate determination. \*\*P < 0.01.



Figure 2. Kaplan-Meier overall survival curves according to the CCAT2 expression level. OSCC patients with high CCAT2 expression showed a significantly poorer prognosis than those with low CCAT2 expression (log-rank test, P = 0.003).

were calculated, and a probability level of 0.05 was chosen for statistical significance.

#### Result

LncRNA CCAT2 is upregulated in OSCC tissues and oral cancer cell lines

LncRNA CCAT2 expression levels were investigated in 102 paired OSCC tissues and adjacent histologically normal tissues by qRT-PCR. CCAT2 expression was significantly higher in tumor tissues compared with adjacent normal tissues (P < 0.01, **Figure 1A**). Expression was also examined by qRT-PCR in three oral cancer cell lines (Tca8113, SCC25 and CAL27) and an immortalized oral keratinocyte cell line HOK16E6E7. This experiment showed that CCAT2 expression was higher in oral cancer cell lines than in HOK16E6E7 (P < 0.01, **Figure 1B**).

Relationship between IncRNA CCAT2 expression levels and clinicopathological features

To assess the correlation of IncRNA CCAT2 expression with clinicopathological data, CCAT2 expression levels in tumor tissues were categorized as low or high in relation

to the median value of relative CCAT2 expression (3.46-fold). Clinicopathological factors were analyzed in the high and low CCAT2 expression groups. As shown in **Table 1**, there was no correlation between the relative CCAT2 expression levels and age, gender, tumor location, or tumor size (P > 0.05), but the relative CCAT2 expression levels were significantly positively correlated with TNM stage (P = 0.010), tumor grade (P = 0.003), and distant metastasis (P < 0.001). Taken together, these observations indicated that increased CCAT2 expression

	Univariate analysis			Multivariate analysis		
Variable	Risk ratio	95% CI	P value	Risk ratio	95% CI	P value
Age	1.335	0.598-2.373	0.612			
≥ 60 vs. < 60						
Gender	0.612	0.654-2.370	0.708			
Male vs. Female						
Tumor location	1.516	0.824-2.910	0.564			
Tongue vs. (Floor of mouth + Buccal mu- cosa Hard palate Upper or lower gingival)						
Tumor size	1.805	0.712-3.335	0.489			
T1 + T2 vs. T3 + T4						
Tumor grade	2.845	1.552-5.417	0.008	2.455	1.341-5.152	< 0.001
G1 vs. G2 + G3						
Distant metastasis	3.581	1.652-7.526	< 0.001	3.064	1.580-6.473	< 0.001
Yes vs. No						
TNM Stage	3.154	1.306-6.058	< 0.001	2.847	1.522-5.937	< 0.001
+    vs.     +  V						
CCAT2	2.945	1.506-5.974	0.002	2.718	1.429-5.682	< 0.001
High vs. Low						

Table 2. Prognostic factors in Cox proportional hazards model

sion is associated with the progression and development of OSCC.

High-level expression of IncRNA CCAT2 predicts poor prognosis in OSCC patients

Kaplan-Meier analysis and log-rank test were used to evaluate the effects of IncRNA CCAT2 expression and the clinicopathological characteristics on overall survival of OSCC patients. The results showed that patients with high CCAT2 expression had a significantly poorer prognosis than those with low expression (P <0.01, Figure 2). Univariate analysis showed that the relative level of CCAT2 expression, TNM stage, tumor grade, and distant metastasis were correlated with overall survival rate of patients with OSCC (P < 0.05, Table 2). Multivariate analysis indicated that CCAT2 expression level, TNM stage, tumor grade, and distant metastasis were independent prognostic indicators for the overall survival of patients with OSCC (P < 0.05, Table 2). The results suggested that expression of CCAT2 in OSCC patients can be developed as an independent prognostic factor.

## Suppressing CCAT2 expression decreases cell proliferation, migration and invasion in vitro

To further investigate the role of CCAT2 in human oral cancer cells, CCAT2 specific siRNA

(si-CCAT2) was transfected into Tca8113 cells, respectively. Nonspecific siRNA was used as a negative control (si-NC). As shown in **Figure 3A**, cells transfection with si-CCAT2 showed a significant decreased mRNA expression of CCAT2 compared to the si-NC group (P < 0.05).

MTT assays showed that the cell growth rate was downregulated in the si-CCAT2 transfected Tca8113 cells compared with the si-NC group (P < 0.05, Figure 3B). Furthermore, to analyze the role of IncRNA CCAT2 in cell migration and invasion, wound healing assays and transwell invasion assays were performed with Tca8113 cells. Wound healing assays showed that the migration ability of Tca8113 cells transfected with si-CCAT2 was significantly decreased compared with the si-NC group (P < 0.05, Figure 3C). Transwell invasion assay revealed that the invasion capacity of Tca8113 cells transfected with si-CCAT2 was notably down-regulated compared to si-NC group (P < 0.05, Figure 3D). Taken together, these data demonstrated that downregulation of IncRNA CCAT2 expression can inhibit cell proliferation, migration and invasion of oral cancer cells in vitro.

#### Discussion

The sequencing of the human genome revealed that the coding portion of the genome represents less than 2% of the genome. The remain-



Figure 3. The knockdown of CCAT2 inhibits proliferation, migration and invasion in Tca8113 cells. A. qRT-PCR revealed that CCAT2 was efficiently knocked down by treatment with si-CCAT2 in Tca8113 cells. B. Tca8113 cells trasfected with si-CCAT2 displayed significantly lower proliferation ability compared with those transfected with si-NC. C. Tca8113 cells trasfected with si-CCAT2 displayed significantly lower migration ability compared with those transfected with si-NC. D. Tca8113 cells trasfected with si-CCAT2 displayed significantly lower migration ability compared with those transfected with si-NC. D. Tca8113 cells trasfected with si-CCAT2 displayed significantly lower invasion ability compared with those transfected with si-NC. Results are expressed as means  $\pm$  SD for three replicate determinations. \**P* < 0.05.

ing 98% of transcription products of the genome consists of non-coding RNA sequences, including microRNAs and IncRNAs [17]. The aberrant expressions of specific IncRNAs in cancer could mark the spectrum of disease progression and these IncRNAs may serve as independent biomarkers for diagnosis and prognosis [18].

Several cancer-related IncRNAs have been identified, but only a few OSCC-related IncRNAs have been characterized. HOTAIR was found to be upregulated in the majority of OSCC and was associated with metastasis, the stage and histological differentiation [19]. HOTAIR overexpression can contribute to the regulation of E-cadherin through binding to EZH2 and H3-K27me3 with the E-cadherin promoter, which promote the metastasis and invasion of OSCC cells [20]. Furthermore, overexpression of Inc-RNA UCA1 also could promote metastatic ability of tongue squamous cell carcinoma cells [21]. However, the role and function of IncRNA CCAT2 in OSCC remains unknown.

In the present study, we explored the clinical significance of IncRNA CCAT2 in OSCC patients for the first time. By using gRT-PCR, we found that IncRNA CCAT2 was increased in OSCC tissues and oral cancer cell lines to a greater extent than in adjacent non-tumor tissues and normal human oral keratinocyte cell line. We also revealed that the relative expression level of IncRNA CCAT2 was associated with TNM stage and distant metastasis of OSCC patients. Furthermore, we analyzed a correlation between IncRNA CCAT2 expression level and prognosis of OSCC. Our results showed patients with high IncRNA CCAT2 expression had a shorter overall survival rate than those with low IncRNA CCAT2 group. These findings were further supported by the univariate and multivariate analyses of Cox proportional hazards regression model, indicating that the expression of IncRNA CCAT2 could be an independent factor for predicting the prognosis of OSCC patients. Therefore, our data suggested that increased expression of IncRNA CCAT2 was associated with a high risk of death from OSCC.

Recent studies suggest that the expression levels of IncRNA CCAT2 were significantly elevated in esophageal squamous cell carcinoma tissues and were correlated with lymph node metastasis [11]. Additionally, silencing CCAT2 by siRNA led to inhibition of proliferation and invasion in non-small cell lung cancer cell lines [14]. To further understand the underlying mechanism of CCAT2 in OSCC progression, in vitro experiments were conducted. We found that down-regulated expression of IncRNA CCAT2 significantly decreased proliferation, migration and invasion capability of lung cancer cells in vitro. These data further support the importance of CCAT2 in cellular biology and oncogenesis of oral cancer cells and indicate that CCAT2 is involved in the development and progression of OSCC.

In summary, our studies demonstrated that IncRNA CCAT2 expression was up-regulated in OSCC and was associated with the biological aggressiveness and progression of OSCC. Moreover, down-regulated expression of CCAT2 could inhibit the proliferation, migration and invasion of oral cells in vitro. These findings demonstrated that IncRNA CCAT2 could serve as a potential biomarker and therapeutic target for OSCC.

#### Disclosure of conflict of interest

None.

Address correspondence to: Dr. Niangou Zhou, Department of Stomatology, 421 Hospital of PLA, 468 Xingang Zhonglu, Guangzhou 510318, Guangdong, China. Tel: 86-20-61636300; E-mail: huk0218@163. com

#### References

- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
- [2] Dissanayaka WL, Pitiyage G, Kumarasiri PV, Liyanage RL, Dias KD, Tilakaratne WM. Clinical and histopathologic parameters in survival of

oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113: 518-525.

- [3] Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013; 152: 1298-1307.
- [4] Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell 2011; 145: 178-181.
- [5] Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. IncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013; 500: 598-602.
- [6] Chen FJ, Sun M, Li SQ, Wu QQ, Ji L, Liu ZL, Zhou GZ, Cao G, Jin L, Xie HW, Wang CM, Lv J, De W, Wu M, Cao XF. Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma metastasis and poor prognosis. Mol Carcinog 2013; 52: 908-915.
- [7] Bhan A, Mandal SS. LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. Biochim Biophys Acta 2015; 1856: 151-164.
- [8] Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ, Ma WL. High expression of long non-coding RNA ANRIL is associated with poor prognosis in hepatocellular carcinoma. Int J Clin Exp Pathol 2015; 8: 3076-3082.
- [9] Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, Liu YW, Zhang EB, Liu XH, De W. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer 2014; 14: 319.
- [10] Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafà R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G. Patiin GA. Gotlev DC. Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K. Taniguchi I. Song MA. Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K. Mori M. Sieuwerts AM. Martens JW. Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S, Fodde R, Calin GA. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in co-Ion cancer. Genome Res 2013; 23: 1446-1461.
- [11] Zhang X, Xu Y, He C, Guo X, Zhang J, He C, Zhang L, Kong M, Chen B, Zhu C. Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2015; 111: 834-839.
- [12] Wang CY, Hua L, Yao KH, Chen JT, Zhang JJ, Hu JH. Long non-coding RNA CCAT2 is up-regulat-

ed in gastric cancer and associated with poor prognosis. Int J Clin Exp Pathol 2015; 8: 779-785.

- [13] Redis RS, Sieuwerts AM, Look MP, Tudoran O, Ivan C, Spizzo R, Zhang X, de Weerd V, Shimizu M, Ling H, Buiga R, Pop V, Irimie A, Fodde R, Bedrosian I, Martens JW, Foekens JA, Berindan-Neagoe I, Calin GA. CCAT2, a novel long noncoding RNA in breast cancer: expression study and clinical correlations. Oncotarget 2013; 4: 1748-1762.
- [14] Qiu M, Xu Y, Yang X, Wang J, Hu J, Xu L, Yin R. CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of nonsmall cell lung cancer. Tumour Biol 2014; 35: 5375-5380.
- [15] Edge SB, Byrd DR, Compton CC. American joint committee on cancer: cancer staging manual. 7th edition. New York, NY: Springer; 2010.
- [16] World Health Organization. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. International Agency for Research on Cancer (IARC) Press; 2005.

- [17] Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Martínez JA, Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J 2015; 29: 3595-3611.
- [18] Gu Y, Chen T, Li G, Yu X, Lu Y, Wang H, Teng L. LncRNAs: emerging biomarkers in gastric cancer. Future Oncol 2015; 11: 2427-2441.
- [19] Wu J, Xie H. Expression of long noncoding RNA-HOX transcript antisense intergenic RNA in oral squamous cell carcinoma and effect on cell growth. Tumour Biol 2015; 36: 8573-8.
- [20] Wu Y, Zhang L, Zhang L, Wang Y, Li H, Ren X, Wei F, Yu W, Liu T, Wang X, Zhou X, Yu J, Hao X. Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. Int J Oncol 2015; 46: 2586-2594.
- [21] Fang Z, Wu L, Wang L, Yang Y, Meng Y, Yang H. Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol 2014; 117: 89-95.